Fundraising Fox
🦊/People
Sign in

Roderick Verhelst

Investor

Partner at Bioqube Ventures

Brussels

Writes $100K – $5M checks · typically $1.5M

Find your path to Roderick

192 people in our graph share verified history with Roderick — schools, employers, funds. One of them is your warm intro.

Katrin GeyskensunlockedRoderick: together at KU Leuven (2003–2011)
×3Roderick: together at KU Leuven
×3Roderick: together at Degroof Petercam
Roderick: together at Confo Therapeutics

About

Partner at Bioqube Ventures focused on early-stage therapeutics, who joined in 2022 with over a decade of life science investing experience, previously at PMV where he helped form, finance and exit startups such as GST, Bluebee, Dualyx and Flamingo Therapeutics, and earlier worked as an equity research analyst at Degroof Petercam. He holds a PhD in Bioengineering from KU Leuven and an MBA from Solvay Brussels School.

Contact· self-published, not guessed

Invests in

Biotech

Experience

  1. Bioqube VenturesPartner at Bioqube Venturescurrent2025 — present
  2. Bioqube VenturesPrincipal at Bioqube Ventures2022 — 2025Hasselt, Flemish Region, Belgium
  3. Temmune TherapeuticsBoard Membercurrent2024 — present
  4. Commit BiologicsBoard Membercurrent2022 — present
  5. PMV - Doe- en DurfbedrijfPrincipal Life Sciences & Care2021 — 2022
  6. PMV - Doe- en DurfbedrijfSenior Investment Manager Life Sciences & Care2019 — 2021Brussels, Brussels Region, Belgium
  7. PMV - Doe- en DurfbedrijfInvestment Manager Life Sciences & Care2016 — 2019Brussels, Brussels Region, Belgium
  8. DualyxBoard Member2020 — 2022
  9. miDiagnosticsBoard Member2019 — 2022Leuven
  10. BlueBeeBoard Observer2020 — 2021
  11. Flamingo TherapeuticsBoard Member2020 — 2021
  12. Confo TherapeuticsBoard Member2020 — 2021Ghent, Flemish Region, Belgium
  13. Global Stem cell TechnologyBoard Member2018 — 2019Ghent
  14. Degroof PetercamSell-side analyst Healthcare2012 — 2016Brussels, Brussels Region, Belgium
  15. KU LeuvenPHD Student2007 — 2011Leuven

Skills & more

Banking1Financial Analysis5Investments6Finance2Customer Service1Equities2Project Management2Capital Markets4Corporate Finance2Management1

Languages Dutch · English · French

From Roderick's professional profile.

Investments

Board seats

Aelin TherapeuticsBluebeeConfo TherapeuticsDualyxFlamingo TherapeuticsGSTmiDiagnostics

Per the firm's website.

Colleagues at Bioqube Ventures

Alexander Demoulin
Associate at Bioqube Ventures
Clement Salque
Associate at Bioqube Ventures
Debora Dumont
Managing Partner at Bioqube Ventures
Dirk Reyn
Managing Partner at Bioqube Ventures
Geert Tackaert
Finance Director at Bioqube Ventures
Jacques Mizrahi
Venture Partner at Bioqube Ventures
Janine Schuurman
Senior Advisor at Bioqube Ventures
Jon Edwards
Managing Partner at Bioqube Ventures

Frequently asked questions

Who is Roderick Verhelst?
Partner at Bioqube Ventures focused on early-stage therapeutics, who joined in 2022 with over a decade of life science investing experience, previously at PMV where he helped form, finance and exit startups such as GST, Bluebee, Dualyx and Flamingo Therapeutics, and earlier worked as an equity research analyst at Degroof Petercam. He holds a PhD in Bioengineering from KU Leuven and an MBA from Solvay Brussels School.
Where does Roderick Verhelst work?
Roderick Verhelst is Partner at Bioqube Ventures.
What does Roderick Verhelst invest in?
Roderick Verhelst invests in Biotech.
What check size does Roderick Verhelst write?
Roderick Verhelst typically writes checks of $100K – $5M.
What boards does Roderick Verhelst sit on?
Roderick Verhelst holds tracked board seats at Aelin Therapeutics, Bluebee, Confo Therapeutics, Dualyx, Flamingo Therapeutics, GST, miDiagnostics.
Where did Roderick Verhelst go to school?
Roderick Verhelst studied at Solvay Brussels School of Economics and Management (Master of Business Administration (M.B.A.), Business Administration and Management); KU Leuven (Doctor of Philosophy (Ph.D.), Bioscience Engineering); KU Leuven (Master's Degree, Biochemistry).

Same school

Shared employers